ADAdrian Duek

Adrian Duek

*This is an algorithmically generated author record based on publicly available information.

Adrian Duek has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Immature Platelet Fraction as a Surrogate Marker of Thrombo-Inflammation in Hospitalized COVID-19 Patients

    by Adrian Duek, Alexandra Zimin, Yael Hershkop, Michal Cipok, Amir Cohen, Merav Leiba

    Although COVID-19 is associated with significant thrombo-inflammatory complications, reliable biomarkers to guide antithrombotic therapy remain limited. Immature platelet fraction (IPF) reflects platelet turnover and may indicate heightened thrombotic risk. We retrospectively analyzed 133 hospitalized COVID-19 patients (median age 68 years) at a single center. IPF and inflammatory markers (WBC, ANC, D-dimer, LDH, CRP) were measured on admission. Correlations between IPF and these biomarkers were assessed overall and in clinical subgroups (age, sex, disease severity, comorbidities, and treatment). We found that IPF was positively correlated with WBC and ANC in patients less than 70 years old (r = 0.36 and 0.33, respectively; p < 0.05), males, and those with moderate-to-severe disease. Among patients with congestive heart failure, IPF correlated strongly with D-dimer (r = 0.78, p = 0.013). Similar associations were observed in patients requiring enoxaparin or antiplatelet therapy. No significant correlations were found in patients age 70 or older. Based on these findings, we conclude that elevated IPF is associated with increased inflammatory and thrombotic activity in hospitalized COVID-19 patients, especially in younger, male, and more severe cases. These findings suggest IPF may serve as a dynamic marker for thrombo-inflammation and help identify patients who might benefit from more intensive antithrombotic therapy. Larger studies are warranted to validate IPF as a biomarker for personalized management of COVID-19.


  • Outcomes of Fedratinib in Routine Treatment of Ruxolitinib-Resistant or -Refractory Patients with Primary and Post-Polycythemia Vera or Essential Thrombocythemia Myelofibrosis: A Nationwide Retrospective Study

    by Adrian Duek, Alexandra Tzinman, Kira Maziuk, Assaf Levy, Martin Ellis, Galia Stemer, Adi Shacham Abulafia, Amos Cohen, Noa Lavi, Aaron Ronson, et al.

    Introduction: In recent years, fedratinib, a selective JAK2 inhibitor, has emerged as a potential therapeutic option for patients who have failed or are intolerant to ruxolitinib. Despite the promising results observed in clinical studies, real-world evidence from the USA and Europe suggests that the efficacy of fedratinib may be less conclusive. We report the characteristics, treatment patterns, and clinical outcomes of patients with myelofibrosis (MF) treated with fedratinib following ruxolitinib failure in Israel’s clinical practice. Methods: This retrospective patient chart review included adults with a physician-reported diagnosis of MF, who initiated fedratinib after discontinuing ruxolitinib. Descriptive analyses characterized patient characteristics, clinical outcomes, and treatment patterns from MF diagnosis through ruxolitinib and fedratinib treatment. Results: We extracted data for 16 eligible patients. Approximately 62.5% of the patients were female, and the median age was 77 (range: 63–85) years. The median duration of ruxolitinib therapy was 17 months (range: 3–84) months. Before the initiation of fedratinib, the median spleen size by palpation was 15.5 cm below the costal margin (range: 4–22 cm). After 3 months the median spleen size was 13 cm below the costal margin (range: 2–21 cm). Only 2 patients showed minimal improvement after 6 months, while 3 patients progressed, and 2 patients showed no change in the spleen size. The spleen response did not improve after 12 months of treatment. At this point, the median spleen size was 19 cm below the costal margin (range: 2–30 cm). Regarding the MF-related symptoms, 43.75% (n = 7) of patients reported some improvement, 37.5% (n = 6) showed no changes, whereas 18.75% (n = 3) of the population complained of worsening. Gastrointestinal toxicity was the most frequent adverse effect of the drug, while 31% of patients died. Conclusion: Our observations showed that in MF patients who have failed to ruxolitinib, the therapeutic value from fedratinib may be modest, especially when exposure time to ruxolitinib was more than 12 months. Early switching from ruxolitinib to fedratinib may yield a better result.


  • Non-coding RNAs regulate novel signaling pathways in AL amyloidosis that are targetable by FDA approved drugs PA38 (#269)

    by Oshrat Hershkovitz-Rokah, Tal Zvida, Eli Muchtar, Mali Salmon-Divon, Angela Dispenzieri, Benjamin Bender, Adrian Duek, Merav Leiba, Moshe E., Ofer Shpilberg

    **Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was | POSTER

    • 1 October 2022
      • Vol. 24  (10) , 629-633

    Mitigating the Interference of Daratumumab with Immunofixation Electrophoresis: A Single-center Experience Using the Hydrashift 2/4 Kit

    by Adrian Duek, Emmanuel Lellouche, Sharon Ben Baruch, Reut Mashiach, Yafit Segman, Gabriel Bryk, Merav Leiba

    Background: Multiple myeloma (MM) accounts for approximately 10% of hematological malignancies. The monoclonal immunoglobulin G kappa (IgG-kappa) daratumumab can bind to CD38 on MM cells and be detected in serum immunofixation (IF), causing pitfalls in M-protein quantification. Objectives: To determine the efficacy of mitigating the interference of IgG MM treated with daratumumab. Methods: Levels of Ig, free light chains (FLC) kappa (kappa) and lambda (lambda), serum protein electrophoresis (SPE)/IF, and Hydrashift 2/4 assays were assessed following manufacturers instructions in three patients. Results: Patient 1 was a 70-year-old male diagnosed with IgG-lambda MM. The IF distinguished two monoclonal bands (IgG-kappa and IgG-lambda). With the Hydrashift assay, the daratumumab-anti-da-ratumumab immune complex shifted the IgG-kappa to the alpha zone, suggesting that the monoclonal IgG-kappa band corresponded to daratumumab. Patient 2 was a 63-year-old male with IgG-kappa MM who was receiving daratumumab once every other week. SPE/IF assay revealed a faint monoclonal IgG-kappa band in the y zone. A stronger monoclonal band was observed after administration. The IgG-kappa band disappeared on the Hydrashift assay, while the daratumumab-anti-daratumumab complex appeared as a broad smear in the alpha-region. Patient 3, a 63-year-old male diagnosed with IgG-lambda MM, was receiving daratumumab once every other month. The IF assay showed two distinct bands (IgG-kappa and IgG-lambda) post-daratumumab administration. The shift to the alpha zone of the IgG-kappa bands on the Hydrashift assay confirmed that the addition-al band observed post-infusion was due to the daratumumab. Conclusions: The Hydrashift assay can help distinguish dara-tumumab from endogenous M-spike.